Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ustekinumab in primary biliary cholangitis with inadequate response to ursodeoxycholic acid
2011-000554-31Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ustekinumab in primary biliary cholangitis (PBC) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: ALP response at Week 28. Started Jul 2011; status: completed.
02
Drugs
ustekinumab
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2011-000554-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000554-31.